| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | -$40.7M | ROE | — |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $120.7M | Trading Days | 294 |
| 52W High | 403.10 |
| 52W Low | 5.44 |
| % Off High | −98.02% |
| YTD | −95.12% | 1Y | −96.10% |
| Since incept. (ann.) | −93.41% |
| Ann. Volatility (1Y) | 174.10% | Ann. Volatility (3Y) | 161.56% |
| Sharpe (1Y) | −0.48 | Sharpe (3Y) | −0.42 |
| Max Drawdown (1Y) | −98.55% | Max Drawdown (3Y) | −98.55% |
| Beta (3Y, vs SPY) | 4.57 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| ANIX | Anixa Biosciences Inc | $119.8M | — |
| PEPG | PepGen Inc. | $126.6M | — |
| SPRB | SPRUCE BIOSCIENCES, INC. | $114.5M | — |
| NGEN | NERVGEN PHARMA CORP. | $128.2M | — |
| PMN | ProMIS Neurosciences Inc. | $130.2M | — |
| GNLX | GENELUX Corp | $130.9M | — |
| UNCY | Unicycive Therapeutics, Inc. | $131.9M | — |
| MIST | Milestone Pharmaceuticals Inc. | $133.2M | — |
| HURA | TuHURA Biosciences, Inc./NV | $135.6M | — |
| AARD | Aardvark Therapeutics, Inc. | $140.1M | — |
| ADCT | ADC Therapeutics SA |
| $141.2M |
| — |
| OGI | ORGANIGRAM GLOBAL INC. | $103.0M | — |
